About Sangamo Therapeutics, Inc. - Common Stock (SGMO)
Sangamo Therapeutics is a biotechnology company focused on developing groundbreaking gene-editing therapies and genomic medicine to address a range of genetic diseases and disorders. By leveraging its expertise in gene modulation and genome editing technologies, including zinc finger proteins, the company aims to create innovative treatments that can permanently alter or correct genetic mutations at the DNA level. Sangamo is committed to advancing its pipeline of therapeutic candidates through rigorous research and clinical trials, collaborating with a variety of partners to expedite the development of transformative therapies for patients in need. Read More
Sangamo Therapeutics (SGMO) reported Q2 2025 results with revenue missing estimates at $18.31M but a narrower loss of $0.08/share. Shares fell 9% post-earnings despite positive Fabry disease trial progress.
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced positive topline results from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease.
